Related references
Note: Only part of the references are listed.Circulating Fibroblast Growth Factor 23 in Patients with End-Stage Renal Disease Treated by Peritoneal Dialysis Is Intact and Biologically Active
Takashi Shimada et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community
Majd A. I. Mirza et al.
ATHEROSCLEROSIS (2009)
Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population
Majd A. I. Mirza et al.
ATHEROSCLEROSIS (2009)
Fibroblast Growth Factor 23 and Left Ventricular Hypertrophy in Chronic Kidney Disease
Orlando M. Gutierrez et al.
CIRCULATION (2009)
Cardiovascular and Noncardiovascular Mortality Among Patients Starting Dialysis
Dinanda J. de Jager et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Phosphorus Binders and Survival on Hemodialysis
Tamara Isakova et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2009)
A blueprint for randomized trials targeting phosphorus metabolism in chronic kidney disease
Tamara Isakova et al.
KIDNEY INTERNATIONAL (2009)
Does FGF23 toxicity influence the outcome of chronic kidney disease ?
Mohammed Shawkat Razzaque
NEPHROLOGY DIALYSIS TRANSPLANTATION (2009)
High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients
Guillaume Jean et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2009)
Rosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis
Bengt C. Fellstroem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Disordered mineral metabolism in hemodialysis patients: An analysis of cumulative effects in the Hemodialysis (HEMO) Study
Ron Wald et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2008)
Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: The Dialysis Outcomes and Practice Patterns Study (DOPPS)
Francesca Tentori et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2008)
FGF-23-Klotho signaling stimulates proliferation and prevents vitamin D-induced apoptosis
Damian Medici et al.
JOURNAL OF CELL BIOLOGY (2008)
Oral active vitamin D is associated with improved survival in hemodialysis patients
Manuel Naves-Diaz et al.
KIDNEY INTERNATIONAL (2008)
Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis
Orlando M. Gutierrez et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Vitamin D levels and early mortality among incident hemodialysis patients
M. Wolf et al.
KIDNEY INTERNATIONAL (2007)
Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: The mild to moderate kidney disease (MMKD) study
Danilo Fliser et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2007)
The emerging role of the fibroblast growth factor-23-Klotho axis in renal regulation of phosphate homeostasis
Mohammed S. Razzaque et al.
JOURNAL OF ENDOCRINOLOGY (2007)
Prevention of cardiovascular events in end-stage renal disease:: Results of a randomized trial of fosinopril and implications for future studies
F. Zannad et al.
KIDNEY INTERNATIONAL (2006)
Plasminogen activator inhibitor-1 deficiency has renal benefits but some adverse systemic consequences in diabetic mice
Sarah J. Collins et al.
NEPHRON EXPERIMENTAL NEPHROLOGY (2006)
Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism
J Cunningham et al.
KIDNEY INTERNATIONAL (2005)
Sevelamer hydrochloride and calcium bicarbonate reduce serum fibroblast growth factor 23 levels in dialysis patients
F Koiwa et al.
THERAPEUTIC APHERESIS AND DIALYSIS (2005)
Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis
C Wanner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease
O Gutierrez et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2005)
Serum phosphate levels and mortality risk among people with chronic kidney disease
B Kestenbaum et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2005)
Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization
AS Go et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers
T Larsson et al.
KIDNEY INTERNATIONAL (2003)
Share Paper
